You are here: Industry Insights > Humira

News List

Humira may spend most on TV, but Xeljanz, Taltz and Breo notch highest view rates fiercepharma
August 10, 2017
Contrary to popular opinion, TV viewers aren't changing the channels often when it comes to pharma TV ads.
Boehringer starts clinical study on interchangeability between adalimumab biosimilar candidate and U cphi-online
July 31, 2017
First study in the US to investigate an interchangeability designation for an adalimumab biosimilar candidate.
Humira’s Patent Protection Lawsuit Lost Again, the World’s Top-selling Drug to Gradually Fall off en-cphi.cn
July 14, 2017
In less than two months after Coherus BioSciences succeeded in winning a key intellectual property lawsuit on AbbVie’s Humira, another biological company seeking to launch a biosimilar rival to Humira, a rheumatoid arthritis drug, has scored the same vict
Biogen’s Imraldi, an adalimumab biosimilar candidate referencing Humira, granted positive opinion by cphi-online
June 27, 2017
If approved, Imraldi will be the third anti-TNF biosimilar in Biogen’s portfolio in Europe.
Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab bio worldpharmanews
June 16, 2017
Boehringer Ingelheim has announced results from the pivotal Phase III VOLTAIRE®-RA(1) study.
Many Targeting AbbVie’s Top-selling Drug, the High Profit of Humira Will Not Continue en-cphi.cn
April 21, 2017
The best-selling drug in the world: Humira does not look good anymore. The assessment results of ICER, a cost-effectiveness watchdog, are that: Humira isn’t worth its current price.
FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's Humira (adalimumab drugs.com
April 06, 2017
AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) approved the inclusion of moderate to severe fingernail psoriasis data in the Humira (adalimumab) prescribing information for patients with moderate to severe chronic plaque ps
Humira had a big lead among the 50 hottest drugs in 2016 and become the five-time champion en-cphi
February 24, 2017
The company sales and the sales of each drug have attracted much attention, with the 2016 financial reports issued by the international pharmaceutical giants in succession recently.
Boehringer Ingelheim biosimilar candidate to Humira accepted for EMA and FDA regulatory review worldpharmanews
January 20, 2017
Boehringer Ingelheim announced that BI 695501, its adalimumab biosimilar candidate to Humira®*, has been accepted for regulatory review by the European Medicines Agency (EMA) and the U.S Food and Drug Administration (FDA).
Boehringer Ingelheim biosimilar candidate to Humira accepted for EMA and FDA regulatory review firstwordpharma
January 19, 2017
Boehringer Ingelheim announced today that BI 695501, its adalimumab biosimilar candidate to Humira®*, has been accepted for regulatory review by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Previous page 1 2 3 4 5 6 7 Next page